Octacosanol

Reviewed on 9/17/2019

What other names is Octacosanol known by?

1-Octacosanol, Hexacosanol (26-C), N-octacosanol, Octacosyl Alcohol, Tetracosanol (24-C), Tétracosanol (24-C), Triacontanol (30-C).

What is Octacosanol?

Octacosanol is a chemical found in a variety of plants, including sugar cane and wheat germ oil. It is chemically similar to vitamin E.

Octacosanol is used to improve exercise performance including strength, stamina, and reaction time. It is also used for herpes infections, skin diseases, Parkinson's disease, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), high cholesterol, and “hardening of the arteries” (atherosclerosis).

Be careful not to confuse octacosanol with policosanol.

SLIDESHOW

Vitamin D Deficiency: How Much Vitamin D Is Enough? See Slideshow

Insufficient Evidence to Rate Effectiveness for...

  • Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Early research suggests that octacosanol does not improve symptoms of ALS.
  • Parkinson's disease. Developing research suggests that octacosanol might improve symptoms in some people with Parkinson's disease.
  • Improving athletic performance including strength, stamina, and reaction time.
  • Herpes infections.
  • Skin diseases.
  • High cholesterol.
  • “Hardening of the arteries” (atherosclerosis).
  • Other conditions.
More evidence is needed to rate the effectiveness of octacosanol for these uses.

How does Octacosanol work?

Octacosanol might help improve the way our body uses oxygen.

Are there safety concerns?

There is not enough information to know if octacosanol is safe.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Not enough is known about the use of octacosanol during pregnancy and breast-feeding. Stay on the safe side and avoid use.

Parkinson's disease: Octacosanol might make some symptoms of Parkinson's disease worse if it is used with the Parkinson's disease medication levodopa/carbidopa. Don't use this combination.

Are there any interactions with medications?


Levodopa/Carbidopa (Sinemet)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Levodopa/carbidopa (Sinemet) is used for Parkinson's disease. Taking octacosanol along with levodopa/carbidopa (Sinemet) might make Parkinson's disease symptoms worse. Do not take octacosanol if you are taking levodopa/carbidopa (Sinemet).

Dosing considerations for Octacosanol.

The appropriate dose of octacosanol depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for octacosanol. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

CONTINUE SCROLLING FOR RELATED SLIDESHOW

QUESTION

Next to red peppers, you can get the most vitamin C from ________________. See Answer

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors

Reviewed on 9/17/2019
References

Alcocer, L., Fernandez, L., Campos, E., and Mas, R. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia. Int.J.Tissue React. 1999;21(3):85-92. View abstract.

Aleman, C. L., Mas, R., Hernandez, C., Rodeiro, I., Cerejido, E., Noa, M., Capote, A., Menendez, R., Amor, A., Fraga, V., and . A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol.Lett. 1994;70(1):77-87. View abstract.

Aleman, C. L., Puig, M. N., Elias, E. C., Ortega, C. H., Guerra, I. R., Ferreiro, R. M., and Brinis, F. Carcinogenicity of policosanol in mice: an 18-month study. Food Chem.Toxicol. 1995;33(7):573-578. View abstract.

Arruzazabala, M. L., Carbajal, D., Mas, R., Valdes, S., and Molina, V. Pharmacological Interaction Between Policosanol and Nitroprusside in Rats. J Med Food 2001;4(2):67-70. View abstract.

Arruzazabala, M. L., Molina, V., Carbajal, D., Valdes, S., and Mas, R. Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukot.Essent.Fatty Acids 1993;49(3):695-697. View abstract.

Arruzazabala, M. L., Noa, M., Menendez, R., Mas, R., Carbajal, D., Valdes, S., and Molina, V. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz.J Med Biol.Res 2000;33(7):835-840. View abstract.

Barocci, S., Ginevri, F., Valente, U., Torre, F., Gusmano, R., and Nocera, A. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation 2-27-1999;67(4):534-538. View abstract.

Cabrera, L., Rivero, B., Magraner, J., Sierra, R., Gonzalez, V., Uribarri, E., Laguna, A., Cora, M., Tejeda, Y., Rodriguez, E., and Velazquez, C. Stability studies of tablets containing 5 mg of policosanol. Boll.Chim.Farm. 2003;142(7):277-284. View abstract.

Cabrera, L., Uribarri, E., Laguna, A., Sierra, R., Mederos, D., Gonzalez, M., and Gonzalez, V. Study of the interaction between policosanol and excipients. Boll.Chim.Farm. 2002;141(2):138-142. View abstract.

Carbajal, D., Arruzazabala, M. L., Mas, R., Molina, V., and Valdes, S. Effect of policosanol on experimental thrombosis models. Prostaglandins Leukot.Essent.Fatty Acids 1994;50(5):249-251. View abstract.

Castano, G., Mas, Ferreiro R., Fernandez, L., Gamez, R., Illnait, J., and Fernandez, C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52(2):115-125. View abstract.

Castano, G., Mas, R., Fernandez, L., Gamez, R., and Illnait, J. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003;54(1):25-38. View abstract.

Castano, G., Mas, R., Gamez, R., Fernandez, L., and Illnait, J. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55(4):361-371. View abstract.

Cholesterol-lowering action of policosanol compares well to that of pravastatin and lovastatin. Cardiovasc.J.S.Afr. 2003;14(3):161. View abstract.

Fontani, G., Maffei, D., and Lodi, L. Policosanol, reaction time and event-related potentials. Neuropsychobiology 2000;41(3):158-165. View abstract.

Gamez, R., Aleman, C. L., Mas, R., Noa, M., Rodeiro, I., Garcia, H., Hernandez, C., Menendez, R., and Aguilar, C. A 6-Month Study on the Toxicity of High Doses of Policosanol Orally Administered to Sprague-Dawley Rats. J Med Food 2001;4(2):57-65. View abstract.

Gamez, R., Maz, R., Arruzazabala, M. L., Mendoza, S., and Castano, G. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. Drugs R.D. 2005;6(1):11-19. View abstract.

Gouni-Berthold, I. and Berthold, H. K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am.Heart J. 2002;143(2):356-365. View abstract.

Hargrove, J. L., Greenspan, P., and Hartle, D. K. Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp.Biol Med (Maywood.) 2004;229(3):215-226. View abstract.

Janikula, M. Policosanol: a new treatment for cardiovascular disease? Altern.Med.Rev. 2002;7(3):203-217. View abstract.

Mas, R., Castano, G., Fernandez, J., Gamez, R. R., Illnait, J., Fernandez, L., Lopez, E., Mesa, M., Alvarez, E., and Mendoza, S. Long- term effects of policosanol on older patients with Type 2 diabetes. Asia Pac.J Clin Nutr. 2004;13(Suppl):S101. View abstract.

McCarty, M. F. An ezetimibe-policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects. Med Hypotheses 2005;64(3):636-645. View abstract.

McCarty, M. F. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen. Med.Hypotheses 2002;59(3):268-279. View abstract.

Menedez, P., Prosper, F., Bueno, C., Arbona, C., San Miguel, J. F., Garcia-Conde, J., Sola, C., Hornedo, J., Cortes-Funes, H., and Orfao, A. Sequential analysis of CD34+ and. Leukemia 2001;15(3):430-439. View abstract.

Menendez, R., Amor, A. M., Gonzalez, R. M., Fraga, V., and Mas, R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol.Res 1996;29(2):253-257. View abstract.

Menendez, R., Fraga, V., Amor, A. M., Gonzalez, R. M., and Mas, R. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav. 8-1-1999;67(1):1-7. View abstract.

Menendez, R., Marrero, D., Mas, R., Fernandez, I., Gonzalez, L., and Gonzalez, R. M. In vitro and in vivo study of octacosanol metabolism. Arch Med Res 2005;36(2):113-119. View abstract.

Menendez, R., Mas, R., Amor, A. M., Gonzalez, R. M., Fernandez, J. C., Rodeiro, I., Zayas, M., and Jimenez, S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br.J.Clin.Pharmacol. 2000;50(3):255-262. View abstract.

Mesa, A. R., Mas, R., Noa, M., Hernandez, C., Rodeiro, I., Gamez, R., Garcia, M., Capote, A., and Aleman, C. L. Toxicity of policosanol in beagle dogs: one-year study. Toxicol.Lett. 1994;73(2):81-90. View abstract.

Mirkin, A., Mas, R., Martinto, M., Boccanera, R., Robertis, A., Poudes, R., Fuster, A., Lastreto, E., Yanez, M., Irico, G., McCook, B., and Farre, A. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int.J.Clin.Pharmacol.Res. 2001;21(1):31-41. View abstract.

Noa, M., Mas, R., and Mesa, R. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol.Res 2001;43(1):31-37. View abstract.

Noa, M., Mas, R., and Mesa, R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 12-1-1998;67(2):125-132. View abstract.

Noa, M., Mas, R., Mendoza, S., Gamez, R., Mendoza, N., and Gonzalez, J. Policosanol prevents bone loss in ovariectomized rats. Drugs Exp.Clin Res 2004;30(3):117-123. View abstract.

Noa, M., Mendoza, S., Mas, R., and Mendoza, N. Effect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague-Dawley rats. Drugs R.D. 2003;4(1):29-35. View abstract.

Prat, H., Roman, O., and Pino, E. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]. Rev.Med.Chil. 1999;127(3):286-294. View abstract.

Rodriguez-Echenique, C., Mesa, R., Mas, R., Noa, M., Menendez, R., Gonzalez, R. M., Amor, A. M., Fraga, V., Sotolongo, V., and Laguna, A. Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem.Toxicol. 1994;32(6):565-575. View abstract.

Taylor, J. C., Rapport, L., and Lockwood, G. B. Octacosanol in human health. Nutrition 2003;19(2):192-195. View abstract.

Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997;36:293-7. View abstract.

Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65. View abstract.

Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int.J.Clin.Pharmacol.Res. 2002;22:55-66. View abstract.

Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int.J.Clin.Pharmacol.Res. 1999;19:105-116. View abstract.

Castano G, Mas R, Fernandez JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J.Gerontol.A Biol.Sci.Med.Sci. 2001;56:M186-M192. View abstract.

Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20:153-63. View abstract.

Castano G, Mas R, Fernandez L, et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int.J.Clin.Pharmacol.Res. 2001;21:43-57. View abstract.

Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol.Endocrinol. 2000;14:187-195. View abstract.

Castano G, Mas R, Gamez R, et al. Concomitant use of policosanol and beta-blockers in older patients. Int J Clin Pharmacol.Res 2004;24:65-77. View abstract.

Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int.J.Clin.Pharmacol.Res. 2002;22:89-99. View abstract.

Castano G1, Mas R, Fernandez JC, et al. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R.D. 2002;3:159-172. View abstract.

Chen JT, Wesley R, Shamburek RD, et al. Meta-Analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005;25:171-83. View abstract.

Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int.J.Clin.Pharmacol.Res. 1999;19:117-127. View abstract.

Kabir Y, Kimura S. Distribution of radioactive octacosanol in response to exercise in rats. Nahrung 1994;38:373-7. View abstract.

Kato S, Karino K, Hasegawa S, et al. Octacosanol affects lipid metabolism in rats fed on a high-fat diet. Br J Nutr 1995;73:433-41. View abstract.

Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14. View abstract.

Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on obese patients with Type II Hypercholesterolemia. Asia Pac.J Clin Nutr. 2004;13(Suppl):S102.

Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin.Pharmacol.Ther. 1999;65:439-447. View abstract.

Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32. View abstract.

Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203. View abstract.

Norris FH, Denys EH, Fallat RJ. Trial of octacosanol in amyotrophic lateral sclerosis. Neurology 1986;36:1263-4. View abstract.

Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987;209:183-9. View abstract.

Snider S. Octacosanol in parkinsonism. Ann Neurol 1984;16:723. View abstract.

Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-7. View abstract.